Results 41 to 50 of about 60,800 (288)
Gabapentin Extended-Release ??? Depomed
Drugs in R & D, 2007 Depomed is developing an extended-release (ER) oral formulation of gabapentin, a GABA receptor agonist commonly used for the treatment of epilepsy and seizures, neuropathic pain and hot flushes. Gabapentin ER is based on the company's proprietary AcuForm drug delivery technology, which is part of the Gastric Retention (GR) family of technologies; this ...
openaire +2 more sources
Comparison of gabapentin and ketotifen in treatment of uremic pruritus in hemodialysis patients [PDF]
, 2016 Objectives: Uremic pruritus is a common problem in hemodialysis patients. Several treatments have been used for decreasing itching in these patients. Gabapentin and ketotifen are two drugs used for treating uremic patients.The aim of this study was to ...
Amirkhanlou, S. +4 more
core +1 more source
Successful medical management of an epidural abscess in a dog [PDF]
, 2017 A seven-month-old entire male dobermann presented with acute onset neck pain and left thoracic limb lameness. The dog had a similar episode eight weeks before presentation that responded to meloxicam.
Durand, Alexane +3 more
core +1 more source
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT Arrhythmias affect approximately half of patients with Costello syndrome (CS, OMIM # 218040), with non‐reentrant atrial tachycardia being the most common. This case describes an infant with Costello syndrome carrying the pathogenic HRAS c.34G>A (p.G12S) variant who developed early‐onset, drug‐refractory multifocal atrial tachycardia (MAT ...
Vanina Taliercio +11 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source
Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
Journal of Central Nervous System Disease, 2012 The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin
Rachel A. Burke, Michele A. Faulkner
doaj +1 more source
Teratogenic effects of gabapentin on the skeletal system of Balb/C mice fetuses [PDF]
, 2009 Objectives: To evaluate the effects of gabapentin )GBP( administration on mice fetuses. Methods: This study was carried out in Birjand University of Medical Sciences during 2008.
Afshar, M. +4 more
core
Intertarsal Joint Stabilization in a Bateleur Eagle (Terathopius ecaudatus) Using a Novel Application of a Braided Suture and Titanium Button System. [PDF]
, 2017 A 32-year-old adult captive male bateleur eagle (Terathopius ecaudatus) with a history of laxity, degenerative joint disease, and varus deviation of the distal left hindlimb for several years was presented for evaluation of left hindlimb lameness and was
De Voe, Ryan S +3 more
core +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga +20 more
wiley +1 more source
Investigations of urethral sphincter activity in mice with bladder hyperalgesia before and after drug administration of gabapentin. [PDF]
, 2019 PurposeThis study investigated the effect of gabapentin on lower urinary tract dysfunction focusing on urethral activities and cystitis-induced hyperalgesia in a mouse model of painful bladder syndrome/interstitial cystitis (PBS/IC). The electromyography&
Chang, Huiyi H +7 more
core